Benzimidazoles for the treatment of cystic and alveolar echinococcosis: What is the consensus?

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 2, 2009, Pages 145-149

  Vuitton, Dominique Angèle ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALPHA INTERFERON; MEBENDAZOLE; NITAZOXANIDE; PLACEBO; PRAZIQUANTEL; ANTHELMINTIC AGENT; BENZIMIDAZOLE DERIVATIVE;

ALOPECIA; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; ECHINOCOCCUS MULTILOCULARIS; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LIVER TOXICITY; MEDICAL DECISION MAKING; MONOTHERAPY; SURGICAL TECHNIQUE; TREATMENT DURATION; ANIMAL; CLINICAL PROTOCOL; CONSENSUS; DRUG EFFECT; PARASITOLOGY;

ALBENDAZOLE; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; CLINICAL PROTOCOLS; CONSENSUS; ECHINOCOCCOSIS; ECHINOCOCCUS GRANULOSUS; ECHINOCOCCUS MULTILOCULARIS; HUMANS; MEBENDAZOLE;

EID: 64049115167     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.7.2.145     Document Type: Editorial

References (41)

1. WHO/OIE. Manual on Echinocccosis in Humans and Animals: a Public Health Problem of Global Concern. Eckert J, Gemmell MA, Meslin F-X, Pawlowski ZS (Eds). Organisation Internationale des Epizooties, Paris, France (2001).
2. Craig PS, Budke CM, Schantz PM et al. Human echinococcosis: a neglected disease? Trop. Med. Health 35, 283-292 (2007).
3. Vuitton DA, Zhou HX, Bresson-Hadni S et al. Epidemiology of alveolar echinococcosis in humans: an update of the situation in Europe and China and new epidemiological trends. Parasitology 127, S87-S107 (2003).
4. WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull. World Health Organ. 74, 231-242 (1996).
5. WHO Informal Working Group on Echinococcosis. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Tropical, 253-261 (2003).
6. Kern P, Wen H, Sato N et al. WHO classification of alveolar echinococcosis: principles and application. Parasitol. Int. 55(Suppl.) S283-S287 (2006).
7. Frider B, Larrieu E, Odriozola M. Long-term outcome of asymptomatic liver hydatidosis. J. Hepatol. 30, 228-231 (1999).
8. Wang Y, He T, Wen X et al. Post-survey follow-up for human cystic echinococcosis in northwest China. Acta Trop. 98, 43-51 (2006).
9. Rausch RL, Wilson JF, Schantz PM, McMahon BJ. Spontaneous death of Echinococcus multilocularis: cases diagnosed serologically (by Em2 ELISA) and clinical significance. Am. J. Trop. Med. Hyg. 36, 576-585 (1987).
10. Bresson-Hadni S, Laplante JJ, Lenys D et al. Seroepidemiologic screening of Echinococcus multilocularis in a European area endemic for alveolar echinococcosis. Am. J. Trop. Med. Hyg. 5, 837-846 (1994).
11. Bartholomot B, Vuitton DA, Harraga S et al. Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China. Am. J. Trop. Med. Hyg. 66, 23-29 (2002).
12. Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am. J. Trop. Med. Hyg. 79(3), 301-311 (2008).
13. Franchi C, Di Vico B, Teggi A. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. Clin. Infect. Dis. 29, 304-309 (1999).
14. Wen H, Zhang HW, Muhmut M, Zou PF, New RR, Craig PS. Initial observation on albendazole in combination with cimetidine for the treatment of human cystic echinococcosis. Ann. Trop. Med. Parasitol. 88(1), 49-52 (1994).
15. Schipper HG, Koopmans RP, Nagy J, Butter JJ, Kager PA, Van Boxtel CJ. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am. J. Trop. Med. Hyg. 63, 270-273 (2000).
16. Chai J, Menghebat, Wei J et al. Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis. Parasitol. Int. 53(1), 3 (2004).
17. Wen H, New RR, Muhmut M et al. Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 113(Pt 2), 111-121 (1996).
18. Horton R J Albendazole in the treatment of human cystic echinococcosis: 12 years of experience. Acta Tropica 64, 79-93 (1997).
19. Kadry Z, Renner EC, Bachmann LM et al. Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br. J. Surg. 92, 1110-1116 (2005).
20. Koch S, Bresson-Hadni S, Miguet J-Ph, Crumbach J-P, Gillet M; European Collaborating Clinicians. Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report. Transplantation 75, 856-863 (2003).
21. Bresson-Hadni S, Vuitton DA, Bartholomot B et al. A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur. J. Gastroenterol. Hepatol. 12, 327-336 (2000).
22. Bresson-Hadni S, Delabrousse E, Blagosklonov O et al. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol. Int. 55(Suppl.), S267-S272 (2006).
23. Reuter S, Buck A, Manfras B et al. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 39(2), 509-517 (2004).
24. Stumpe KD, Renner-Schneiter EC, Kuenzle AK et al. F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy. Infection 35(1), 11-18 (2007).
25. Vutova K, Mechkov G, Vachkov P et al. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann. Trop. Med. Parasitol. 93, 357-365 (1999).
26. Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 342, 1269-1272 (1993).
27. Keshmiri M, Baharvahdat H, Fattahi SH et al. Albendazole versus placebo in treatment of echinococcosis. Trans. R. Soc. Trop. Med. Hyg. 95, 190-194 (2001).
28. Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann. Trop. Med. Parasitol. 88, 295-304 (1994).
29. World Health Organization. PAIR: puncture, aspiration, injection, re-aspiration. An option for the treatment of cystic echinococcosis. WHO, Geneva (2003).
30. Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration - injection - reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin. Infect. Dis. 37, 1073-1083 (2003).
31. Khuroo MS, Dar MY, Yattoo GN et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 104, 1452-1459 (1993).
32. Akhan O, Gumus B, Akinci D, Karcaaltincaba M, Ozmen M. Diagnosis and percutaneous treatment of soft-tissue hydatid cysts. Cardiovasc. Intervent. Radiol. 30, 419-425 (2007).
33. Vuitton DA, Wen H. Treatment of cystic echinococcosis: a combination of general goals and rules, individual decisions and indications. Neth. J. Med. 65, 86-88 (2007).
34. Torgerson PR, Schweiger A, Deplazes P et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J. Hepatol. 49, 72-77 (2008).
35. Cobo F, Yarnoz C, Sesma B et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop. Med. Int. Health 3, 462-466, (1998).
36. Marchiondo AA, Ming R, Andersen FL, Slusser JH, Conder GA. Enhanced larval cyst growth of Echinococcus multilocularis in praziquantel-treated jirds (Meriones unguiculatus). Am. J. Trop. Med. Hyg. 50(1), 120-127 (1994).
37. Stettler M, Rossignol JF, Fink R et al. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int. J. Parasitol. 34, 615-624 (2004).
38. Kern P, Abboud P, Kern W et al. Critical appraisal of nitazoxanide for the treatment of alveolar echinococcosis. Am. J. Trop. Med. Hyg. 79, 119 (2008)
39. Vuitton DA, Zhang SL, Yang Y et al. Survival strategy of Echinococcus multilocularis in the human host. Parasitol. Int. 55(Suppl.), S51-S55 (2006).
40. 2a monotherapy for human echinococcosis. Clin. Infect. Dis. 29, 205-206 (1999).
41. 2a protects mice against a helminth infection of the liver and modulates immune responses. Gastroenterology 124, 1441-1450 (2003).